Table 4.
Cancer Type Distribution Across Studies
| Cancer Type | CARAVAGGIO∗ Agnelli et al. (12); 2020 |
SELECT-D† Young et al. (10); 2018 |
Hokusai VTE Cancer‡ Raskob et al. (9); 2018 |
ADAM-VTE McBane et al. (11); 2019 |
||||
|---|---|---|---|---|---|---|---|---|
| Apixaban (n = 576) | Dalteparin (n = 579) | Rivaroxaban (n = 203) | Dalteparin (n = 203) | Edoxaban (n = 522) | Dalteparin (n = 524) | Apixaban (n = 150) | Dalteparin (n = 150) | |
| Colorectal | 121 (21.0) | 113 (19.5) | 55 (27.0) | 47 (23.0) | 83 (15.9) | 79 (15.1) | 18 (12.2) | 29 (19.6) |
| Upper GI | 23 (4.0) | 31 (5.4) | 15 (7.0) | 26 (12.0) | 33 (6.3) | 21 (4.0) | 7 (4.8) | 4 (2.7) |
| Lung | 105 (18.2) | 95 (16.4) | 22 (11.0) | 25 (12.0) | 77 (14.8) | 75 (14.3) | 32 (21.8) | 19 (12.8) |
| Breast | 79 (13.7) | 76 (13.1) | 20 (10.0) | 20 (10.0) | 64 (12.3) | 60 (11.5) | 16 (10.9) | 12 (8.1) |
| Genitourinary | 66 (11.5) | 73 (12.6) | 25 (13.0) | 17 (11.0) | 65 (12.5) | 71 (13.5) | 13 (8.7) | 14 (9.3) |
| Gynecological | 60 (10.4) | 59 (10.2) | 18 (9.0) | 25 (12.0) | 47 (9.0) | 63 (12.0) | 14 (9.5) | 15 (10.1) |
| Pancreatic or hepatobiliary | 44 (7.6) | 43 (7.4) | 12 (10.0) | 13 (6.0) | 49 (9.4) | 40 (7.6) | 23 (15.6) | 24 (16.2) |
| Head and neck§ | 14 (2.4) | 8 (1.4) | 0 (0.0) | 0 (0.0) | — | — | 0 (0.0) | 0 (0.0) |
| Brain tumor | 0 (0) | 0 (0) | 1 (1.0) | 2 (1.0) | || | || | 3 (2.0) | 5 (3.4) |
| Bone/soft tissue | 11 (1.9) | 7 (1.2) | 2 (1.0) | 0 (0.0) | — | — | 3 (2.0) | 1 (0.7) |
| Skin: melanoma | 4 (0.7) | 7 (1.2) | — | — | — | — | 0 (0.0) | 4 (2.7) |
| Hematological malignancy | 33 (5.7) | 52 (9.0) | 14 (7.0) | 17 (9.0) | 56 (10.7) | 55 (10.5) | 13 (8.9) | 14 (9.5) |
| Other | 16 (2.8) | 15 (2.6) | 10 (5.0) | 11 (7.0) | 48 (9.2) | 60 (11.5) | 0 (0.0) | 2 (1.4) |
Values are n (%).
∗
Basal cell or squamous cell carcinoma of the skin, primary brain tumor or known intracerebral metastases, and acute leukemia were not included in the CARAVAGGIO trial.
†
Basal cell or squamous cell carcinoma of the skin were not included in the SELECT-D trial.
‡
Basal cell or squamous cell carcinoma of the skin were not included in the Hokusai VTE Cancer trial.
§
Other than brain tumors.
ǁ
Data not available, because brain tumors were included under “other tumors”.